Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:

The 26 th Annual B. Riley Securities Investor Conference Date: Wednesday, May 20, 2026 Location: The Ritz-Carlton, Marina Del Rey, California

The 23 rd Annual Craig-Hallum Institutional Investor Conference Date: Thursday, May 28, 2026 Location: Depot Renaissance Hotel Minneapolis, Minnesota

Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 at 9:55-10:25AM ET Location: New York, New York Webcast: Click Here

There are no presentations for the B. Riley Securities and Craig-Hallum conferences.

About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX ® , ALKINDI SPRINKLE ® , DESMODA™, GALZIN ® , HEMANGEOL ® , PKU GOLIKE ® , Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia ® , ET-700, ET-800 and ZENEO ® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com .

Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: [email protected]